Rapidly Progressive Glomerulonephritis
Conditions
Interventions
Control Group:sing conventional drug immunosuppressive therapy (glucocorticoids +/- immunosuppressants), and not using extracorporeal blood purification treatment to clear pathogenic antibodies (inclu
Intervention Group:On the basis of conventional drug treatment, protein A immunoadsorption therapy is used.
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 70 years old; 2. No gender restrictions; 3. Positive for serum anti-glomerular basement membrane antibodies (GBM+) or positive for anti-neutrophil cytoplasmic antibodies (ANCA+); 4. Clinical diagnosis of rapidly progressive nephritis; 5. The patient or legal representative agrees and signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Pregnant women; 2. Individuals with consciousness disturbances who are unable to communicate; 3. Individuals with psychiatric disorders who are non-compliant with treatment; 4. Patients currently receiving angiotensin-converting enzyme inhibitor (ACEI) therapy and cannot discontinue it; 5. Patients with relative contraindications to extracorporeal circulation therapy (such as shock, hypercoagulable state, severe bleeding or bleeding tendency, etc.); 6. Individuals with a history of intolerance to plasma exchange and allergies to other extracorporeal circulation therapies; 7. Individuals with multiple organ dysfunction; 8. Other situations deemed unsuitable for participation in the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in titer of autoantibodies (GBM or ANCA); | — |
Secondary
| Measure | Time frame |
|---|---|
| the change of IgG;The rate of renal function recovery; | — |
Countries
China
Contacts
Public ContactYingying Yang
Department of Nephrology, West China Hospital, Sichuan University
Outcome results
None listed